Piramal Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	5.54×	1.40×	0.27×	0.15×	1.07×
	−0.12×	−2.58×	0.54×	0.26×	3.60×
	3.2%	1.0%	6.9%	5.6%	−0.7%
	0.53×	0.53×	0.59×	0.55×	0.52×
	2.27×	2.20×	1.93×	1.94×	2.14×
	−2.6%	−4.3%	1.1%	0.2%	−2.9%
	−4.0%	−4.0%	1.1%	0.2%	−2.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PPLPHARMA₹230.78

Piramal Pharma Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB SYNGENE GLAND WOCKPHARMA ASTERDM COHANCE LALPATHLAB NATCOPHARMMcap ₹30,628 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	1.07	0.15	0.27	1.40	5.54
Interest Burden (Pretax/EBIT) ×	3.60	0.26	0.54	-2.58	-0.12
EBIT Margin %	-0.68	5.58	6.87	1.02	3.19
Asset Turnover ×	0.52	0.55	0.59	0.53	0.53
Financial Leverage (Assets/Equity) ×	2.14	1.94	1.93	2.20	2.27
ROE (5-step product, year-end total equity) %	-2.94	0.23	1.13	-4.29	-2.58
ROE (owners' profit / average owners' equity) %	-2.77	0.24	1.14	-4.00	-4.00

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.